Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 254

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 254
---
 variables in PWERM. As of June 30, 2024, a 5.0% decrease in discount rate would increase
the fair value of the warrants to $154; a 5.0% increase in discount rate would decrease the fair value of the warrants to $143.

| b. | On March 11, 2023, the Company issued 53,031                                                 
 warrants in connection with the issuance of its convertible notes. which are exercisable     
 into convertible preferred D-2 shares. The warrants were exercisable until December 31, 2023 
 and have expired on December 31, 2023, as they were not exercised.                           |

<div align='center'>F-11</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | SHORT-TERM LOAN |

| a. | In April 2024, the Company received the                                                     
 grant from the Horizon 2020 Program and as such, repaid the outstanding balance of the loan 
 received in August 2023 at the amount of $325.                                              |

| b. | In January 2024, the Company received a                                                    
 $150 loan from several lenders, including from two directors of the Company (the “January  
 2024 Loan”). Pursuant to the agreement reached in October 2024 (the “2024 Amendment”)      
 with the January 2024 Loan lenders , the January 2024 Loan Agreements have been extended   
 until the earlier of an IPO consummation date, or until August 31, 2025 (the “Maturity     
 Date”), and shall bear interest at 8% per annum until maturity, commencing as of September 
 1, 2024. In addition, at the Maturity Date, the Company shall pay the Lenders an aggregate 
 risk premium equal to $50 . Furthermore, upon the occurrence of an IPO, the January 2024   
 Loan lenders shall be granted warrants to purchase such number of ordinary shares equal to 
 two times the Loan amount, based on a price per share equal to 75% of the lowest price per 
 share of the Company’ ordinary shares during the first five trading days as of such        
 IPO consummation.                                                                          |

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES |

| 1.